Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia
October 15, 2024 05:30 AM Eastern Daylight Time ATLANTA–(BUSINESS WIRE)–Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it will launch a multinational Phase 3 clinical trial in December 2024 of zelpultide alfa (rhSP-D) …
Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia
Company plans to initiate a multinational pivotal trial of zelpultide alfa (rhSP-D) in Q4/2024 beginning in Europe. The study will enroll more than 300 neonates born at 23 weeks to 27 weeks and 6 days ATLANTA–(BUSINESS WIRE)– Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury …
2024 Neonatal & Developing Lung Abstract Achievement Awardee, Raquel Arroyo, PhD, PharmD
Congratulations to Raquel Arroyo, PhD, PharmD on winning the 2024 Neonatal & Developing Lung Abstract Achievement Award. Raquel Arroyo, PhD, PharmD is the Director of Clinical Sciences at Airway Therapeutics. She has been working with SP-D for 10+ years in academia and industry. Raquel has published several papers and presented in international scientific meetings. Her work …
Airway Therapeutics Featured in Drug Discovery News
Neonatal drug development comes out of the Dark Ages Left out of clinical trials for years, preterm infants have very few drugs developed just for them. Regulators, industry, and neonatologists plan to fix that. Read more: Drug Discovery News July/August 2023 or PDF
Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Favorable safety profile confirmed also in fourth and final cohort including babies born at earliest gestational age of 23 to 24 weeks Interim analysis is complete and full results are expected by October 2023 Company expects to begin a Phase 3 trial by end of 2023 ATLANTA, GEORGIA (June 5, 2023) – Airway Therapeutics, Inc., …
Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
DSMC finds no safety concerns, allows use of highest dose for continued administration. Interim analysis of the trial expected in next month Company opens Spanish subsidiary to lead EU clinical trials ATLANTA, GEORGIA (April 11, 2023) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury …
Airway Therapeutics Joins C-Path’s International Neonatal Consortium
TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”) has become a member of its International Neonatal Consortium (INC). Airway is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. Airway is …
Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS
Authors: Ryan R. Manning, Ryan E. Holcomb, Derrick S. Katayama, Giovanni M. Pauletti, Shawn N. Grant, Jan S. Rosenbaum, and Mark Cornell Manning Characterization of Oligomer Formation of Surfactant Protein-D (SP-D) Using AF4-MALLS Abstract: Background: Surfactant protein-S (SP-D) is a naturally occurring lung protein with the potential to treat pulmonary infections. A recombinant surfactant protein-D (SP-D) has …
Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Further plans for expansion in Europe include up to ten clinical trial sites across Spain by end of Q32022 and up to three sites in Italy by end of 2022 Zelpultide alfa has been approved as the generic name for our AT-100 (rhSP-D) by the two governing organizations, the United States Adopted Names (USAN) Council …
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, GEORGIA (March 31, 2022) – Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, …
- 1
- 2
- 3
- …
- 5
- Next Page »
